Page 4 - Dr Reddy's

India trials for Russia's Covid vaccine may start in few weeks: Dr Reddy's

The trials are part of a deal between the Russian Direct Investment Fund and Dr Reddy's.

Russian vaccine on its way to India, pact signed with Dr Reddy's for trials

Talks are also on with five major Indian manufacturers here to produce the vaccine for India and the world

Russia to supply 100 million doses of Sputnik V vaccine to Dr Reddy's

The Russian Direct Investment Fund said that the deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine in India

Dr Reddy's Laboratories launches drug to treat infections in US market

Ciprodexis used in adults and children 6 months of age or older to treat certain types of infections caused by certain germs called bacteria

Dr Reddy's: Strong Q1 show in spite of disruption lifts sentiment

Normalising US and India sales likely to drive earnings in FY21

Dr Reddy's Q1 PAT falls 13% to Rs 579 cr, revenue up by 15% to Rs 4,417 cr

Commenting on the results, co-chairman and MD, G V Prasad said "the current quarter's financial performance has been strong across all parameters

Aarti Drugs to Tata Comm: Earnings rise for 15 firms in Covid-19 economy

These companies reported an increase in revenue and/or profit before tax for the March quarter

Sun Pharma stock sheds 15% on price fixing concerns, slow portfolio ramp-up

The near-term worry for the company is the ongoing investigation by the US Department of Justice related to price fixing and cartelisation by generic companies

Dr Reddy's gets 1 observation from USFDA after inspecting Hyderabad plant

Earlier, the drug major had said that the US health regulator has issued a Form 483 with two observations after inspecting the facility but later it was issued revised Form 483 with one observation

Wockhardt sells part of branded biz to Dr Reddy's for Rs 1850 crore

Deal would help Wockhardt focus on international operations, novel pipeline R&D

Dr Reddy's to acquire part of Wockhardt's India business for Rs 1,850 crore

The agreement comprises a portfolio of 62 brands in multiple therapy areas such as respiratory, neurology, and dermatology.

Dr Reddy's reaping benefits of domestic market focus, outperforms peers

Firm has outperformed domestic pharma market in 7 of last 8 quarters

Dr Reddy's launches cancer treatment drug Bortezomib in the US market

Bortezomib is an active ingredient similar to that of the once blockbuster cancer treatment Velcade of Millennium Pharmaceuticals

Indian pharma cos with bigger US presence face more FDA scrutiny: Analysts

Big entities such as Aurobindo and Dr Reddy's have been currently filing for new product approvals from multiple sites

Develop entire value chain: Dr Reddy's MD tells pharma companies

US-China trade war is going to give us a window of opportunity to expand our industry, says G V Prasad

Pharma industry needs to develop entire value chain: Dr Reddy's G V Prasad

According to Prasad, the relevance of Indian pharma sector as a provider of affordable alternative to the world remains intact

Sharp earnings downgrades for Dr Reddy's, Zee Entertainment and IOC

Among other Nifty companies, ZEEL has seen an earnings cut of over 8%

Domestic-oriented companies on fund managers' radar, says analyst

Further, fund managers say the markets could continue to remain polarised as growth companies are likely to fetch a premium, especially when the economy is going through a trough

PSAI segment decline pulls down Dr Reddy's Q1 show

Earnings were driven by one-off gains

Dr Reddy's launches therapeutic equivalent of Vitamin K1 in US

Dr Reddy's Phytonadione Injectable Emulsion USP, 10 mg/ml Single-Dose Ampules is available in 1 ml Ampule containing 10 mg/ml of Phytonadione